Expression profile of apoptotic and proliferative proteins in hypoxic HUVEC treated with statins

International Journal of Oncology

Volumn 46, Issue 2, 2015, Pages 677-684

  Li, Xiaochen ^a   Liu, Xiansheng ^a   Xu, Yongjian ^a   He, Yuanzhou ^a   Liu, Jin ^a   Xie, Min ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cell cycle; Endothelial cells; Hypoxia; Mitochondrial apoptosis; Statins

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 3; CASPASE 9; CYCLIN B1; CYCLIN D1; CYTOCHROME C; FLUINDOSTATIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MITOCHONDRIAL PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN 6; SURVIVIN; TUMOR NECROSIS FACTOR RECEPTOR 1; VASCULOTROPIN; VOLTAGE DEPENDENT ANION CHANNEL; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID; TUMOR PROTEIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL CYCLE PHASE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HYPOXIA; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; BIOSYNTHESIS; CELL HYPOXIA; DRUG EFFECTS; GENE EXPRESSION REGULATION;

APOPTOSIS; CELL HYPOXIA; CELL PROLIFERATION; FATTY ACIDS, MONOUNSATURATED; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INDOLES; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION;

EID: 84918562771     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2780     Document Type: Article

References (38)

1. Nishida N, Yano H, Nishida T, Kamura T and Kojiro M: Angiogenesis in cancer. Vasc Health Risk Manag 2: 213-219, 2006.
2. Uzzan B, Nicolas P, Cucherat M and Perret GY: Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 64: 2941-2955, 2004.
3. Bremnes RM, Camps C and Sirera R: Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 51: 143-158, 2006.
4. Z hao HC, Qin R, Chen XX, et al: Microvessel density is a prognostic marker of human gastric cancer. World J Gastroenterol 12: 7598-7603, 2006.
5. Vaupel P: The role of hypoxia-induced factors in tumor progression. Oncologist 9 (Suppl 5): S10-S17, 2004.
6. Fang L, Choi SH, Baek JS, et al: Control of angiogenesis by AIBP-mediated cholesterol efflux. Nature 498: 118-122, 2013.
7. Wang CY, Liu PY and Liao JK: Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 14: 37-44, 2008.
8. Grosser N, Hemmerle A, Berndt G, et al: The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radic Biol Med 37: 2064-2071, 2004.
9. Newton CJ, Ran G, Xie YX, et al: Statin-induced apoptosis of vascular endothelial cells is blocked by dexamethasone. J Endocrinol 174: 7-16, 2002.
10. Asakage M, Tsuno NH, Kitayama J, et al: 3-Hydroxy-3- methylglutaryl-coenzyme A reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest. Anticancer Drugs 15: 625-632, 2004.
11. Weis M, Heeschen C, Glassford AJ and Cooke JP: Statins have biphasic effects on angiogenesis. Circulation 105: 739-745, 2002.
12. Gross A, McDonnell JM and Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899-1911, 1999.
13. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van O osterom AT and De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56: 549-580, 2004.
14. Polet F and Feron O: Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force. J Intern Med 273: 156-165, 2013.
15. Wise DR, Ward PS, Shay JE, et al: Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci USA 108: 19611-19616, 2011.
16. Manalo DJ, Rowan A, Lavoie T, et al: Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105: 659-669, 2005.
17. Humar R, Kiefer FN, Berns H, Resink TJ and Battegay EJ: Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 16: 771-780, 2002.
18. O sende JI, Ruiz-Ortega M, Blanco-Colio LM and Egido J: Statins to prevent cardiovascular events in hypertensive patients. The ASCOT-LLA study. Nephrol Dial Transplant 19: 528-531, 2004.
19. Pande A, Lombardo J, Spangenthal E and Javle M: Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res 27: 3465-3470, 2007.
20. O smak M: Statins and cancer: current and future prospects. Cancer Lett 324: 1-12, 2012.
21. Lavie O, Pinchev M, Rennert HS, Segev Y and Rennert G: The effect of statins on risk and survival of gynecological malignancies. Gynecol Oncol 130: 615-619, 2013.
22. Cardwell CR, Hicks BM, Hughes C and Murray LJ: Statin use after colorectal cancer diagnosis and survival: a populationbased cohort study. J Clin Oncol 32: 3177-3183, 2014.
23. Schaefer CA, Kuhlmann CR, Weiterer S, et al: Statins inhibit hypoxia-induced endothelial proliferation by preventing calciuminduced ROS formation. Atherosclerosis 185: 290-296, 2006.
24. Deichmann R, Lavie C and Andrews S: Coenzyme q10 and statininduced mitochondrial dysfunction. Ochsner J 10: 16-21, 2010.
25. Liu Y, Samuel BS, Breen PC and Ruvkun G: Caenorhabditis elegans pathways that surveil and defend mitochondria. Nature 508: 406-410, 2014.
26. Satoh M, Fujimoto S, Horike H, et al: Mitochondrial damageinduced impairment of angiogenesis in the aging rat kidney. Lab Invest 91: 190-202, 2011.
27. Loboda A, Jazwa A, Jozkowicz A, Molema G and Dulak J: Angiogenic transcriptome of human microvascular endothelial cells: effect of hypoxia, modulation by atorvastatin. Vascul Pharmacol 44: 206-214, 2006.
28. Crosbie J, Magnussen M, Dornbier R, Iannone A and Steele TA: Statins inhibit proliferation and cytotoxicity of a human leukemic natural killer cell line. Biomark Res 1: 33, 2013.
29. Kuo YS, Tang YB, Lu TY, Wu HC and Lin CT: IGFBP-6 plays a role as an oncosuppressor gene in NPC pathogenesis through regulating EGR-1 expression. J Pathol 222: 299-309, 2010.
30. Raykha C, Crawford J, Gan BS, Fu P, Bach LA and O'Gorman DB: IGF-II and IGFBP-6 regulate cellular contractility and proliferation in Dupuytren's disease. Biochim Biophys Acta 1832: 1511-1519, 2013.
31. Grellier P, De Galle B and Babajko S: Expression of insulin-like growth factor-binding protein 6 complementary DNA alters neuroblastoma cell growth. Cancer Res 58: 1670-1676, 1998.
32. DiPaola RS: To arrest or not to G2-M Cell-cycle arrest: commentary re: A.K. Tyagi, et al: Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clin cancer res 8: 3512-3519, 2002. Clin Cancer Res 8: 3311-3314, 2002.
33. Toyoshima H and Hunter T: p27, a novel inhibitor of G1 cyclin- Cdk protein kinase activity, is related to p21. Cell 78: 67-74, 1994.
34. Yin Y, Tainsky MA, Bischoff FZ, Strong LC and Wahl GM: Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70: 937-948, 1992.
35. Basu A and Haldar S: The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod 4: 1099-1109, 1998.
36. Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF and Guillou PJ: Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 86: 886-892, 2002.
37. Z hou M, Gu L, Li F, Zhu Y, Woods WG and Findley HW: DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther 303: 124-131, 2002.
38. Maslov S and Sneppen K: Protein interaction networks beyond artifacts. FEBS Lett 530: 255-256, 2002.